Bank of America Is Dropping $250+ Million on GLP-1s Annually
Business

Bank of America Is Dropping $250+ Million on GLP-1s Annually

Bank of America now allocates 13% of its total employee healthcare budget to GLP-1 weight-loss medications across its 211,000 workforce.

Shyank Dev
Written by Molly Liebergall (Morning Brew)
Edited by ShyankAugust 6, 2026

Bank of America is currently spending more than $250 million per year to cover GLP-1 weight-loss drugs for its workforce. Chief Executive Officer Brian Moynihan highlighted the explosive growth in prescription drug costs, revealing that GLP-1 treatments now consume a massive share of the bank's employee health benefits program.

📈 From Zero to 13% of Healthcare Budget

Just four to five years ago, Bank of America spent essentially zero dollars on weight-loss pharmaceutical coverage. Today, the $250+ million expenditure represents approximately 13% of the bank's entire $2 billion annual healthcare budget for its 211,000 global employees.

Healthcare Spend Breakdown:
[ Other Employee Medical Benefits: 87% ($1.75B) ]
[ GLP-1 Prescription Medications: 13% ($250M+) ]

💉 Corporate America's Healthcare Dilemma

Bank of America's surge in pharmaceutical costs reflects a wider corporate dilemma as demand for breakthrough weight-loss medications like Wegovy and Zepbound reshapes employee benefit strategies:

  • Talent Retention: Comprehensive GLP-1 coverage has rapidly become a prized benefit for recruiting and retaining top talent in competitive sectors.
  • Cost Management: Rising list prices and ongoing treatment requirements create long-term fiscal challenges for self-insured employers.
  • Corporate Policy Shifts: Many Fortune 500 organizations are re-evaluating coverage criteria, requiring prior authorization or step therapy to curb expenditure.
Year       | GLP-1 Annual Expenditure    | Share of Health Budget
-----------+-----------------------------+-----------------------
2021-2022  | ~$0                         | 0%
2026       | $250,000,000+               | ~13%

🔮 What's Next

As pharmaceutical manufacturers develop oral GLP-1 alternatives and competition increases, enterprise benefit managers are closely watching price trajectories. Bank of America and other financial giants are negotiating bulk pricing and structured wellness initiatives to balance employee healthcare satisfaction with long-term cost sustainability.


🔗 Reference

About & Technical Stack

Shyank Akshar

Shyank Akshar

I'm Shyank, a full-stack software engineer specializing in secure, high-scale systems.

Over 5+ years, I've shipped production applications across govtech, fintech, and consumer platforms — systems that handle national-scale authentication, real-time payments, and millions of users in production. I've built official SDKs live across iOS, Android, and React Native; engineered 2FA and biometric security infrastructure trusted by government and enterprise clients; and designed backend systems processing high-throughput transactions with zero tolerance for failure.

I work primarily in Swift and Golang, with deep experience in distributed systems, Apache Kafka, and applied cryptography. I care about building things that hold up under real load and real security scrutiny — not demos, production.

Technical Stack

Languages, platforms, and architectures I build on.

iOS
Swift
GCP
AWS
Java
backend
Golang
Javascript
Typescript
Mongo DB
MySQL
Redis
Kotlin
Kafka
Kubernetes
Docker
Microservices
System Design
Distributed Systems
Recent News